Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic hepatitis C virus (HCV)~* Treatment naive, null or partial responders to previous treatment with peginterferon and ribavirin~* Males and females 18-65 years old~* Body mass index 18 to \< 35 kg/m\^2~* Females must be postmenopausal for at least 2 years or surgically sterile~Exclusion Criteria:~* Cirrhosis or extensive bridging fibrosis~* History of cardiac disease~* Positive screen for certain drugs or alcohol~* Abnormal laboratory results~* Significant sensitivity to any drug~* Positive hepatitis B surface antigen or anti-human immunodeficiency virus antibody~* Use of strong cytochrome P450 3A (CYP3A), cytochrome P450 2C8 (CYP2C8), and organic anion transporting polypeptide 1B1 (OATP1B1) enzyme inducers or inhibitors within 1 month of dosing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ABT-450/r (250/100 mg) and ABT-333 plus RBV in treatment-naïve (Type: EXPERIMENTAL): ABT-450/r (250/100 mg) once daily (QD) and ABT-333 (400 mg) twice daily (BID) plus weight-based ribavirin (RBV) divided BID for 12 weeks in treatment-naïve participants.
- ABT-450/r (150/100 mg) and ABT-333 plus RBV in treatment-naïve (Type: EXPERIMENTAL): ABT-450/r (150/100 mg) once daily (QD) and ABT-333 (400 mg) twice daily (BID) plus weight-based ribavirin (RBV) divided BID for 12 weeks in treatment-naïve participants.
- ABT-450/r (150/100 mg) and ABT-333 plus RBV in non-responders (Type: EXPERIMENTAL): ABT-450/r (150/100 mg) once daily (QD) and ABT-333 (400 mg) twice daily (BID) plus weight-based ribavirin (RBV) divided BID in previous non-responders to pegylated interferon (pegIFN) and RBV.

Based on this trial design, predict the completion outcome and termination type (if applicable).